These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542 [TBL] [Abstract][Full Text] [Related]
7. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Williams DR; Lees AJ; Wherrett JR; Steele JC Neurology; 2008 Feb; 70(7):566-73. PubMed ID: 18268249 [TBL] [Abstract][Full Text] [Related]
8. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Whitwell JL; Tosakulwong N; Botha H; Ali F; Clark HM; Duffy JR; Utianski RL; Stevens CA; Weigand SD; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Ahlskog JE; Dickson DW; Josephs KA Neuroimage Clin; 2020; 25():102152. PubMed ID: 31935638 [TBL] [Abstract][Full Text] [Related]
9. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Schofield EC; Hodges JR; Macdonald V; Cordato NJ; Kril JJ; Halliday GM Mov Disord; 2011 Feb; 26(2):256-63. PubMed ID: 21412832 [TBL] [Abstract][Full Text] [Related]
10. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome. Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918 [TBL] [Abstract][Full Text] [Related]
11. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy. Jellinger KA Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518 [TBL] [Abstract][Full Text] [Related]
12. PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Vasilevskaya A; Taghdiri F; Multani N; Anor C; Misquitta K; Houle S; Burke C; Tang-Wai D; Lang AE; Fox S; Slow E; Rusjan P; Tartaglia MC Front Neurol; 2020; 11():574. PubMed ID: 32754109 [No Abstract] [Full Text] [Related]
13. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Ling H; O'Sullivan SS; Holton JL; Revesz T; Massey LA; Williams DR; Paviour DC; Lees AJ Brain; 2010 Jul; 133(Pt 7):2045-57. PubMed ID: 20584946 [TBL] [Abstract][Full Text] [Related]
14. Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. Street D; Malpetti M; Rittman T; Ghosh BCP; Murley AG; Coyle-Gilchrist I; Passamonti L; Rowe JB Brain Commun; 2021; 3(3):fcab206. PubMed ID: 34541533 [TBL] [Abstract][Full Text] [Related]
15. Gradient subthalamic neurodegeneration and tau pathology in the hypoglossal nucleus as essential pathological markers of progressive supranuclear palsy - Richardson syndrome. Homma T; Mochizuki Y; Hara M; Kamei S; Mizutani T; Takubo H; Isozaki E; Takahashi M; Komori T; Hao H Rev Neurol (Paris); 2020 May; 176(5):353-360. PubMed ID: 32247606 [TBL] [Abstract][Full Text] [Related]